29.2 C
New York
Saturday, June 19, 2021

Here is the latest about Novan Inc. (NOVN) stock

Novan Inc. (NOVN) stock price is gaining momentum in Tuesday’s march 30th pre-market session. It has gained 18.25% as of this writing. Yesterday it closed at $1.37 after going down 4.20%.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



Novan Inc. (NOVN) share prices have decreased by -15.95% over the past week, but are up 100.00% over prices posted in the last quarter. Going further back, the stock’s price has tanked 171.29% over the last 6 months but is up 68.51% in year-to-date trading.

Let’s have a look at the recent developments in the company.

Share purchasing by President and CEO of Novan

On March 26, 2021,70,000 NOVN Shares were purchased by the President and CEO of NovanPaula B Stafford at the average price of $1.43. since then NOVN stock has lost 4.2%

New Board member

On March 02, 2021, Novan announced the election of Steven D. Skolsky to its Board of Directors.

President and Chief Executive Officer of Novan Paula Brown Stafford said that Electing Steve to our board, a leader in the industry with a successful track record in commercialization, marketing strategy, and multiple successful product launches, is invaluable

Recent Financial results

On February 25, 2021, Novan Inc reported full-year 2020 financial results.

2020 Financial highlights

  • Novan reported revenues of $4.9 million for 2020.
  • It reported operating expenses of $31.1 million for the year 2020.
  • research and development expenses were $19.8 million and general and administrative expenses were  $11.3 million for the reported year.
  • 2020 net loss was $29.3million or $0.30per share which compares with the 2019 net loss of ($30.6) million and ($1.17) per share.
  • As of December 31, 2020, the cash and marketable securities balance were $35.9 million.

Successful patient enrollment in Phase 3 clinical study of SB206

On Feb. 01, 2021, Novan announced the completion of patient enrollment in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel which is for the treatment of molluscum contagiosum

Approximately six million people in the U.S are affected by Molluscum contagiosum, a contagious skin infection caused by the molluscipoxviru.

About NOVN

Novan is a biotechnology company that translates the scientifically-proven power of nitric oxide into innovative, first-in-class therapies. Our proprietary platform advances research and development to improve dermatological, women’s health, gastrointestinal conditions, and more.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.